Literature DB >> 8033297

Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells.

S Ohno1, Z H Siddik, Y Kido, L A Zwelling, J M Bull.   

Abstract

An optimal scheduling of hyperthermia and cis-diammine-dichloroplatinum(II) (cisplatin) may increase the therapeutic gain of the combination of these two modalities. In this study, intracellular platinum accumulation, total platinum binding to DNA, and DNA interstrand crosslinks (ISC) were assayed to investigate the molecular mechanisms responsible for the effect of sequencing hyperthermia on the thermal enhancement of cisplatin-induced cytotoxicity in mouse leukemia L1210 cells. Simultaneous treatment with heat (41.5 degrees C, 60 min) and cisplatin produced maximal cell killing with a 4-fold decrease in the 50% growth-inhibitory concentration (IC50) of the platinum complex. Super-additive cell killing was also shown when cells were exposed to heat before cisplatin treatment, whereas no thermal enhancement in cisplatin-mediated cytotoxicity was observed in cells given heat after exposure to cisplatin. These results correlated with the degree of formation of ISC observed in cells following various treatments. A 2- to 3-fold increase in ISC formation was observed in cells given heat before or during cisplatin exposure, whereas heat after cisplatin treatment did not alter either the formation or the reversal of ISC as compared with cisplatin alone. The increased ISC formation was associated with an increase in intracellular platinum accumulation and total platinum binding to DNA in cells given heat before or during cisplatin exposure. These data, showing that hyperthermia potentiates cisplatin cytotoxicity by increasing drug uptake and the formation of DNA adducts without inhibiting the repair of DNA lesions, demonstrate the potential utility of sequencing hyperthermia combined with cisplatin as a clinical anticancer therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8033297     DOI: 10.1007/bf00686037

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  22 in total

1.  Fractionation of DNA from mammalian cells by alkaline elution.

Authors:  K W Kohn; L C Erickson; R A Ewig; C A Friedman
Journal:  Biochemistry       Date:  1976-10-19       Impact factor: 3.162

2.  Effect of cis-diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury.

Authors:  J Wondergem; R E Bulger; F R Strebel; R A Newman; E L Travis; L C Stephens; J M Bull
Journal:  Cancer Res       Date:  1988-01-15       Impact factor: 12.701

3.  Timing of combined hyperthermia and 1,3-bis(2-chloroethyl)-1-nitrosourea or cis-diamminedichloroplatinum in BD IX rats with BT4A tumours.

Authors:  O Mella; O Dahl
Journal:  Anticancer Res       Date:  1985 May-Jun       Impact factor: 2.480

4.  Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia.

Authors:  E L Zakris; M W Dewhirst; J E Riviere; P J Hoopes; R L Page; J R Oleson
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

5.  Factors influencing the sensitivity of two human bladder carcinoma cell lines to cis-diamminedichloroplatinum(II).

Authors:  P Bedford; M C Walker; H L Sharma; A Perera; C A McAuliffe; J R Masters; B T Hill
Journal:  Chem Biol Interact       Date:  1987-01       Impact factor: 5.192

6.  Interaction of hyperthermia and cis-diamminedichloroplatinum(II) alone or combined with radiation in a C3H mammary carcinoma in vivo.

Authors:  J Overgaard; M M Radacic; C Grau
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

7.  Acute systemic toxicity of combined cis-diamminedichloroplatinum and hyperthermia in the rat.

Authors:  O Mella; R Eriksen; O Dahl; O D Laerum
Journal:  Eur J Cancer Clin Oncol       Date:  1987-04

8.  Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model.

Authors:  D S Alberts; Y M Peng; H S Chen; T E Moon; T C Cetas; J D Hoeschele
Journal:  J Natl Cancer Inst       Date:  1980-08       Impact factor: 13.506

9.  Schedule dependent tumour growth delay, DNA cross-linking and pharmacokinetic parameters in target tissues with cis-diamminedichloroplatinum(II) and etanidazole with or without hyperthermia or radiation.

Authors:  B A Teicher; M R Pfeffer; E Alvarez Sotomayor; T S Herman
Journal:  Int J Hyperthermia       Date:  1991 Sep-Oct       Impact factor: 3.914

10.  Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin.

Authors:  L A Zwelling; S Michaels; L C Erickson; R S Ungerleider; M Nichols; K W Kohn
Journal:  Biochemistry       Date:  1981-11-10       Impact factor: 3.162

View more
  16 in total

1.  Synthesis of stress proteins in hyperthermia in the presence of cytotoxic agents.

Authors:  D A Mavletova; G A Dvorkin
Journal:  Dokl Biochem Biophys       Date:  2001 Jul-Aug       Impact factor: 0.788

Review 2.  Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise.

Authors:  Ramez N Eskander; James Cripe; Robert E Bristow
Journal:  Curr Treat Options Oncol       Date:  2014-03

3.  Influence of hyperthermia on efficacy and uptake of carbon nanohorn-cisplatin conjugates.

Authors:  Matthew R DeWitt; Allison M Pekkanen; John Robertson; Christopher G Rylander; Marissa Nichole Rylander
Journal:  J Biomech Eng       Date:  2014-02       Impact factor: 2.097

4.  Multifunctional nanoclusters of NaYF4:Yb3+,Er3+ upconversion nanoparticle and gold nanorod for simultaneous imaging and targeted chemotherapy of bladder cancer.

Authors:  Suehyun K Cho; Lih-Jen Su; Chenchen Mao; Connor D Wolenski; Thomas W Flaig; Wounjhang Park
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2018-12-29       Impact factor: 7.328

5.  Synthesis and characterization of CREKA-conjugated iron oxide nanoparticles for hyperthermia applications.

Authors:  Anastasia M Kruse; Samantha A Meenach; Kimberly W Anderson; J Zach Hilt
Journal:  Acta Biomater       Date:  2014-01-31       Impact factor: 8.947

6.  Synergistic enhancement of cancer therapy using a combination of heat shock protein targeted HPMA copolymer-drug conjugates and gold nanorod induced hyperthermia.

Authors:  Nate Larson; Adam Gormley; Nick Frazier; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2013-04-17       Impact factor: 9.776

7.  Retention of intratumor injections of cisplatinum in murine tumors and the impact on laser thermal therapy for cancer treatment.

Authors:  Sarath Kanekal; Jayne Joo; Michael Bublik; Adir Bababeygy; Christopher Loh; Dan J Castro; Joel A Sercarz; Marcos B Paiva
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-07-08       Impact factor: 2.503

8.  Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.

Authors:  J V Hettinga; W Lemstra; C Meijer; W A Dam; D R Uges; A W Konings; E G De Vries; H H Kampinga
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Molecular mechanisms of cisplatin cytotoxicity in acute promyelocytic leukemia cells.

Authors:  Sanjay Kumar; Paul B Tchounwou
Journal:  Oncotarget       Date:  2015-12-01

Review 10.  Past, Present, and Future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer.

Authors:  Mona Mishra; Nilanchali Singh; Prafull Ghatage
Journal:  Cureus       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.